| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine. This medicine was considered by AWMSG Scrutiny Panel on 07/08/2025. It was considered not suitable for assessment by LOWMAG. |
|
Medicine details |
|
| Medicine name | pegylated liposomal irinotecan (Onivyde®) |
| Formulation | 5.0 mg/ml concentrate for solution for infusion |
| Reference number | 1630 |
| Indication | Treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine based therapy |
| Company | Servier Laboratories Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 31/08/2016 |
| NICE guidance | TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine |
| Further information This medicine was considered by AWMSG scrutiny panel on 07/08/2025. Pegylated liposomal irinotecan (Onivyde®) in conjunction with chemotherapy after progression on gemcitabine-based therapy is not suitable for assessment via the Licensed Medicines One Wales Medicines Assessment Group (LOWMAG). There were no significant new factors which would change the original NICE decision. |
|